{
    "root": "309ea506-42b9-94ff-e063-6294a90ab805",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Valproic Acid",
    "value": "20250318",
    "ingredients": [
        {
            "name": "CORN OIL",
            "code": "8470G57WFM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_195250"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_39867"
        }
    ],
    "indications": {
        "text": "valproic acid capsules indicated : monotherapy adjunctive therapy complex partial seizures ; sole adjunctive therapy simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "valproic acid capsules intended oral . ( 2.1 ) simple complex absence seizures : start 10 15 mg/kg/day , increasing 1-week intervals 5 10 mg/kg/week seizure control limiting side effects ( 2.1 ) safety doses 60 mg/kg/day established ( 2.1 , 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "white , oblong soft-gelatin capsule imprinted pa2120 , contains 250 mg valproic acid bottles 100 \u2019 ( ndc # 69452-150-20 ) . softgels protected moisture humidity stored 59 77\u00b0f ( 15 25\u00b0c ) per container label . dispense tight , light-resistant container defined usp/nf . maalox \u00aeis registered trademark novartis consumer health canada inc. titralac\u2122 registered trademark 3m . depakote \u00aeis registered trademark abbott laboratories .",
    "adverseReactions": "valproic acid capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . valproic acid contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers-huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . valproic acid contraindicated patients known hypersensitivity [ ( 5.12 ) ] . valproic acid contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . prophylaxis migraine headaches : valproic acid contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications_original": "Valproic Acid Capsules are intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1-week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions_original": "Each white, oblong soft-gelatin capsule is imprinted PA2120, contains 250 mg valproic acid in bottles of 100\u2019s (NDC # 69452-150-20).\n                  The softgels should be protected from moisture and humidity and stored between 59 to 77\u00b0F (15 to 25\u00b0C) as per the container label. Dispense in a tight, light-resistant container as defined in the USP/NF.\n                  Maalox\n \n  \u00aeis a registered trademark of Novartis Consumer Health Canada Inc.\n\n \n                  Titralac\u2122 is a registered trademark of 3M.\n                  Depakote\n \n  \u00aeis a registered trademark of Abbott Laboratories.",
    "adverseReactions_original": "Valproic Acid Capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (\n   \n    5.12)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (\n   \n    5.6)]\n  \n   .\n \n  \n                     For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception\u00a0\n  \n   [see Warnings and Precautions (\n   \n    5.2,\n                           5.3,\n   \n    5.4\n                        \n                        ) and Use in Specific Populations (\n                        \n                           8.1\n                        \n                        )].",
    "drug": [
        {
            "name": "Valproic Acid",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_39867"
        }
    ]
}